# EDGAR Filing Document

**Accession Number:** 0001173313
**File Stem:** 0001213900-25-104900
**Filing Date:** 2025-11
**Character Count:** 12127
**Document Hash:** 54d8e808cd002050bbf4f5853d7f94a2
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-104900.hdr.sgml**: 20251103

**ACCESSION NUMBER**: 0001213900-25-104900

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20251103

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251103

**DATE AS OF CHANGE**: 20251103

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ABVC BIOPHARMA, INC.
- **CENTRAL INDEX KEY:** 0001173313
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 260014658
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40700
- **FILM NUMBER:** 251442121

**BUSINESS ADDRESS:**
- **STREET 1:** 44370 OLD WARM SPRINGS BLVD.
- **CITY:** FREMONT
- **STATE:** CA
- **ZIP:** 94538
- **BUSINESS PHONE:** 510-668-0881

**MAIL ADDRESS:**
- **STREET 1:** 44370 OLD WARM SPRINGS BLVD.
- **CITY:** FREMONT
- **STATE:** CA
- **ZIP:** 94538

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** American BriVision (Holding) Corp
- **DATE OF NAME CHANGE:** 20160111

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** METU BRANDS, INC.
- **DATE OF NAME CHANGE:** 20150908

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ECOLOGY COATINGS, INC.
- **DATE OF NAME CHANGE:** 20080821

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 3, 2025

**ABVC BIOPHARMA, INC.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Nevada** | **001-40700** | **26-0014658** |
| (State or other jurisdiction<br> of incorporation) | (Commission File Number) | (IRS Employer<br> Identification No.) |

---

---

| | |
|:---|:---|
| **44370 Old Warm Springs Blvd.**<br> **Fremont, CA** | **94538** |
| (Address of principal executive offices) | (Zip Code) |

---

Registrant's telephone number including area code: **(510) 668-0881**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of Each Class | Trading Symbol | Name of each exchange on which registered |
| Common Stock, par value $0.001 per share | ABVC | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 2.02 Results of Operations and Financial Condition.**

On November 3, 2025, ABVC BioPharma, Inc. (the "Company") issued a press release announcing its financial results for the third quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information reported under this Item 2.02 of Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Neither this Current Report on Form 8-K, nor any exhibit attached hereto, is an offer to sell or the solicitation of an offer to buy the Securities described herein. Such disclosure does not constitute an offer to sell, or the solicitation of an offer to buy nor shall there be any sales of the Company's securities in any state in which such an offer, solicitation or sale would be unlawful. The securities mentioned herein have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements under the Securities Act and applicable state securities laws.

**Item 9.01 Exhibits** 

(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | [Press Release](ea026348101ex99-1_abvcbio.htm) |
| 104 | Cover Page Interactive Data File, formatted in Inline XBRL |

---

**SIGNATURE**

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **ABVC BioPharma, Inc.** | **ABVC BioPharma, Inc.** |
| November 3, 2025 | By: | /s/ Uttam Patil |
|  |  | Uttam Patil |
|  |  | Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

**ABVC BioPharma Reports 230% YoY Licensing Revenue Growth and 181% Asset Expansion in Q3 2025**

Silicon Valley, CA (November 03, 2025) – ABVC BioPharma, Inc.. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in central nervous system (CNS), ophthalmology, and oncology/hematology indications, today announced its financial results for the quarter ended September 30, 2025, and provided an update on recent corporate developments.

![](ex99-1_001.jpg)

Valuations provided above are based on third-party valuation.

**Financial Highlights**

● **Licensing Revenue:** The Company recognized approximately **USD 1.28 million** in licensing revenue for Q3 2025, compared to USD 0.39 million for the same period in 2024, an increase of approximately **230% year-over-year**.

● **Total Assets:** As of September 30, 2025, total assets were **USD 21.18 million**, compared with USD 7.54 million at December 31, 2024, representing an increase of approximately **181%**.

● **Property and Equipment:** Property and equipment (net) totaled **USD 12.06 million**, up from USD 0.51 million at the end of 2024, reflecting a growth of approximately **2,100%** due to recent real-asset investments in Taiwan.

**Operational Highlights**

● **Strategic Asset Investments:** During the third quarter, the Company completed two land acquisitions in Taiwan totaling approximately **USD 11 million**:

● **Puli (Nantou) by AiBtl BioPharma Inc.:** USD 7.67 million for the development of a plant factory for botanical raw materials and new drug substance research.

● **Longtan (Taoyuan) by ABVC BioPharma, Inc.:** USD 3.3 million for agricultural R&D and API cultivation. These investments, together with the planned Vitargus® GMP manufacturing facility, are expected to strengthen the Company's Asia-based production and research capabilities.

● **Global Dual-Core Structure:** ABVC continues to develop its dual-core operations between **Silicon Valley**, focusing on innovation and clinical development through its BioKey platform, and **Taiwan**, which supports manufacturing and development activities.

● **Licensing Programs:** The Company maintains multiple licensing agreements covering CNS, ophthalmology, and oncology pipelines, each providing potential future milestone and royalty income based on development and commercialization progress.

**Corporate Overview**

The Company continues to follow an asset-light business model focused on licensing, partnerships, and collaborative development. Recent investments in physical assets in Taiwan are expected to enhance future research and manufacturing capacity. ABVC seeks to advance its key pipeline assets and to explore additional partnerships that support its long-term growth strategy.

"Our third-quarter results reflect continued progress in both our licensing revenue and asset development activities," said Dr. Uttam Patil, ABVC's Chief Executive Officer. "We remain focused on executing our strategic priorities to create sustainable value for our shareholders over the long term."

About ABVC BioPharma & Its Industry

ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus<sup>®</sup>) under development. For its drug products, the Company utilizes in-licensed technology from its network of world-renowned research institutions to conduct proof-of-concept trials through Phase II of clinical development. The Company's network of research institutions includes Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center. For Vitargus®, the Company intends to conduct pivotal clinical trials (Phase III) through global partnerships.

Forward-Looking Statements

This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential," or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified, and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. None of the outcomes expressed herein are guaranteed. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval to proceed to the next level of the clinical trials or to market our product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

This press release does not constitute an offer to sell, or the solicitation of an offer to buy any of the Company's securities, nor shall such securities be offered or sold in the United States absent registration or an applicable exemption from registration, nor shall there be any offer, solicitation or sale of any of the Company's securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.

Contact:

Uttam Patil

Email: uttam@ambrivis.com